Global Microbial API Market Size study, by Host, by Type, by Site, by End User and Regional Forecasts 2022-2032

Description

Global Microbial API Market is valued approximately at USD 60.3 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 6.91% over the forecast period 2024-2032. Microbial API (Active Pharmaceutical Ingredient) refers to compounds produced by microorganisms, such as bacteria, fungi, or yeast, that have therapeutic effects and are used as active ingredients in pharmaceuticals. These APIs are derived through fermentation processes, where microorganisms are cultivated to produce substances with medicinal properties. Examples include antibiotics like penicillin, which is produced by the mold Penicillium chrysogenum, and other biologically active molecules like statins and immunosuppressants. Microbial APIs (Active Pharmaceutical Ingredients) play a crucial role in the pharmaceutical industry, providing the essential components for manufacturing medications that address a wide range of diseases. The increasing prevalence of chronic illnesses such as Alzheimer's disease and cardiovascular conditions drives the demand for microbial APIs, as these ingredients are vital in developing effective treatments. The pharmaceutical industry's ongoing efforts to find new therapies for chronic diseases underscore the growing importance of microbial APIs in creating essential medications.

The Global Microbial API Market is experiencing significant growth, propelled by several key factors. The rise in chronic diseases worldwide has led to a sustained demand for APIs containing microorganisms. As the pharmaceutical industry faces the challenges of an expanding list of chronic conditions, including heart disease and neurological disorders, the need for innovative treatments becomes imperative. The World Health Organization (WHO) reports that non-communicable diseases account for 71% of global deaths, with cardiovascular diseases alone causing over 18 million deaths in 2021. This highlights the critical role of microbial APIs in developing life-saving medications. Furthermore, the increasing demand for biosimilar and generic medications, driven by the need to reduce healthcare costs, contributes to the market's expansion. The Association for Accessible Medicines reported significant savings to the U.S. healthcare system from generic and biosimilar medications, emphasizing the economic benefits of microbial APIs in drug production.

The key region in the Global Microbial API Market includes North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2023, North America dominates the market in terms of revenue, supported by well-developed healthcare infrastructures, high healthcare spending, and the presence of major pharmaceutical companies' manufacturing and R&D facilities. Europe holds the second-largest market share, driven by rising healthcare costs, increased R&D spending, and a growing generics market. The Asia-Pacific region is expected to witness the fastest growth, fueled by the rapidly expanding pharmaceutical industry in China and India, foreign investments in production facilities, and government initiatives to support domestic manufacturing.

Major market players included in this report are:

Merck & Co., Inc.
DSM
CSPC Pharmaceutical Group Limited
KOLON LIFE SCIENCE
Topfond Pharmaceutical Co., Ltd.
Shandong Lukang Pharmaceutical Co., Ltd.
Teva Pharmaceutical Industries Ltd.
Lonza
Pfizer Inc.
Novartis AG
Sanofi
Johnson & Johnson
GlaxoSmithKline plc

The detailed segments and sub-segment of the market are explained below:

By Host:

Mammalian
Bacterial
Fungal

By Type:

Antibody
Peptide
Protein
Small Molecule
Vaccine

By Site:

In-house
Outsourced

By End User:

Pharmaceutical Companies
Biopharmaceutical Companies
Others

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Microbial API Market Executive Summary

1.1. Global Microbial API Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Host
- 1.3.2. By Type
- 1.3.3. By Site
- 1.3.4. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Microbial API Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Microbial API Market Dynamics

3.1. Market Drivers
- 3.1.1. Rise in prevalence of chronic diseases
- 3.1.2. Increasing demand for biosimilar and generic medications
- 3.1.3. Sustainable manufacturing practices
3.2. Market Challenges
- 3.2.1. High production costs
- 3.2.2. Regulatory hurdles
3.3. Market Opportunities
- 3.3.1. Advancements in microbial fermentation technology
- 3.3.2. Government incentives for sustainable manufacturing

Chapter 4. Global Microbial API Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Microbial API Market Size & Forecasts by Host 2022-2032

5.1. Segment Dashboard
5.2. Global Microbial API Market: Host Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Mammalian
- 5.2.2. Bacterial
- 5.2.3. Fungal

Chapter 6. Global Microbial API Market Size & Forecasts by Type 2022-2032

6.1. Segment Dashboard
6.2. Global Microbial API Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Antibody
- 6.2.2. Peptide
- 6.2.3. Protein
- 6.2.4. Small Molecule
- 6.2.5. Vaccine

Chapter 7. Global Microbial API Market Size & Forecasts by Site 2022-2032

7.1. Segment Dashboard
7.2. Global Microbial API Market: Site Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. In-house
- 7.2.2. Outsourced

Chapter 8. Global Microbial API Market Size & Forecasts by End User 2022-2032

8.1. Segment Dashboard
8.2. Global Microbial API Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 8.2.1. Pharmaceutical Companies
- 8.2.2. Biopharmaceutical Companies
- 8.2.3. Others

Chapter 9. Global Microbial API Market Size & Forecasts by Region 2022-2032

9.1. North America Microbial API Market
- 9.1.1. U.S. Microbial API Market
  - 9.1.1.1. Host breakdown size & forecasts, 2022-2032
  - 9.1.1.2. Type breakdown size & forecasts, 2022-2032
  - 9.1.1.3. Site breakdown size & forecasts, 2022-2032
  - 9.1.1.4. End User breakdown size & forecasts, 2022-2032
- 9.1.2. Canada Microbial API Market
  - 9.1.2.1. Host breakdown size & forecasts, 2022-2032
  - 9.1.2.2. Type breakdown size & forecasts, 2022-2032
  - 9.1.2.3. Site breakdown size & forecasts, 2022-2032
  - 9.1.2.4. End User breakdown size & forecasts, 2022-2032
9.2. Europe Microbial API Market
- 9.2.1. U.K. Microbial API Market
- 9.2.2. Germany Microbial API Market
- 9.2.3. France Microbial API Market
- 9.2.4. Spain Microbial API Market
- 9.2.5. Italy Microbial API Market
- 9.2.6. Rest of Europe Microbial API Market
9.3. Asia-Pacific Microbial API Market
- 9.3.1. China Microbial API Market
- 9.3.2. India Microbial API Market
- 9.3.3. Japan Microbial API Market
- 9.3.4. Australia Microbial API Market
- 9.3.5. South Korea Microbial API Market
- 9.3.6. Rest of Asia Pacific Microbial API Market
9.4. Latin America Microbial API Market
- 9.4.1. Brazil Microbial API Market
- 9.4.2. Mexico Microbial API Market
- 9.4.3. Rest of Latin America Microbial API Market
9.5. Middle East & Africa Microbial API Market
- 9.5.1. Saudi Arabia Microbial API Market
- 9.5.2. South Africa Microbial API Market
- 9.5.3. Rest of Middle East & Africa Microbial API Market

Chapter 10. Competitive Intelligence

10.1. Key Company SWOT Analysis
10.2. Top Market Strategies
10.3. Company Profiles
- 10.3.1. KOLON LIFE SCIENCE
  - 10.3.1.1. Key Information
  - 10.3.1.2. Overview
  - 10.3.1.3. Financial (Subject to Data Availability)
  - 10.3.1.4. Product Summary
  - 10.3.1.5. Market Strategies
- 10.3.2. Topfond Pharmaceutical Co., Ltd.
- 10.3.3. Shandong Lukang Pharmaceutical Co., Ltd.
- 10.3.4. Teva Pharmaceutical Industries Ltd.
- 10.3.5. Lonza
- 10.3.6. Merck & Co., Inc.
- 10.3.7. DSM
- 10.3.8. CSPC Pharmaceutical Group Limited
- 10.3.9. Pfizer Inc.
- 10.3.10. Novartis AG
- 10.3.11. Sanofi
- 10.3.12. Johnson & Johnson
- 10.3.13. GlaxoSmithKline plc

Chapter 11. Research Process

11.1. Research Process
- 11.1.1. Data Mining
- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
11.2. Research Attributes